CIRM Clinical Trials
Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients.

CIRM funds clinical trials across a broad range of diseases and conditions that include rare and genetic disorders, treatment-resistant and refractory diseases, and many forms of cancer. Our involvement in the clinical trial process is vital to transforming potential treatments into available therapies by accelerating pathways to commercialization. Visit our Funding Opportunities page to apply for clinical trial research funding.
0
CIRM-Funded Clinical Trials
Disease Areas | Investigator | Organization | Phase | Trial Status | Target Enrollment | Detail |
---|---|---|---|---|---|---|
COVID-19 Respiratory Disorders |
Prof. John A. Zaia | City of Hope, Beckman Research Institute | Phase 1 | Launching | N/A | |
Bladder or Urinary Tract Disorder | James Yoo | Wake Forest University Health Sciences | Phase 1 | Not yet recruiting | 10 | |
Blood Cancer Solid Tumors |
Professor Irving L Weissman MD | Stanford University | Phase 1 | Completed | 88 | |
COVID-19 Respiratory Disorders |
William van der Touw | Celularity Inc. | Phase 1/2 | Closed | 86 | |
Solid Tumors | Dr. Dennis J Slamon | University of California, Los Angeles | Phase 1 | Completed | 46 | |
Danon Disease Pediatrics |
Dr. Jonathan Schwartz | Rocket Pharmaceuticals, Inc. | Phase 2 | Launching | N/A | |
Lupus, Systemic Lupus Erythematosus (SLE) | Dr. Vaneet Sandhu | Fate Therapeutics, Inc. | Phase 1 | Launching | N/A | |
Immune Disease | Dr. Maria Grazia Roncarolo | Tr1X Inc. | Phase 1 | Launching | N/A | |
Immune Disease Leukocyte Adhesion Deficiency |
Dr. Kinnari Patel | Rocket Pharmaceuticals, Inc. | Phase 1/2 | Completed | 9 | |
Immune Disease Pediatrics Severe Combined Immunodeficiency, X-linked (X-SCID) |
Dr. Judith A Shizuru Wendy Pang |
Stanford University Jasper Therapeutics, Inc. |
Phase 1/2 | Recruiting | 40 | |
Pulmonary Hypertension Vascular Disease |
Dr. Michael I Lewis | Cedars-Sinai Medical Center | Phase 1/2 | Completed | 26 | |
Genetic Disorder Immune Disease Pediatrics Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID) |
Dr. Donald B. Kohn Leslie Meltzer |
University of California, Los Angeles Orchard Therapeutics plc |
Phase 2 | Completed | 10 | |
Immune Disease Pediatrics X-linked Chronic Granulomatous Disease |
Dr. Donald B. Kohn | University of California, Los Angeles | Phase 1/2 | Recruiting | 16 | |
Pediatrics Sickle Cell Disease |
Dr. Donald B. Kohn | University of California, Los Angeles | Phase 1 | Active, not recruiting | 4 | |
Neurological Disorders Other |
Prof. Olivia Kim-McManus | University of California, San Diego | Phase 1/2 | Launching | N/A | |
Arthritis Osteoarthritis |
Dr. Kristen A Johnson | Calibr | Phase 1 | Completed | 60 | |
Bone or Cartilage Disease Hearing Loss Intellectual Disability Metabolic Disorders Vision Loss |
Dr Robert Hayes | Immusoft Corporation | Phase 1 | Launching | N/A | |
Immune Disease Severe Combined Immunodeficiency, X-linked (X-SCID) |
Stephen Gottschalk | St. Jude Children’s Research Hospital | Phase 1/2 | Suspended | 28 | |
Developmental Disorders Spina Bifida |
Dr. Diana L. Farmer | University of California, Davis | Phase 2 | Recruiting | 55 | |
HIV/AIDS Immune Disease |
Steven G. Deeks | University of California, San Francisco | Phase 1/2 | Recruiting | 18 | |
Cystinosis Kidney Failure |
Dr. Stephanie Cherqui | University of California, San Diego | Phase 1/2 | Active, not recruiting | 6 | |
Immune Disease | DR Jonathan Benjamin | ImmPACT-Bio, Inc. | Phase 1/2 | Launching | N/A | |
Muscle Injury | Peter C Belafsky | University of California, Davis | Phase 1/2 | Recruiting | 62 |